Scientists launch national study to track immune weakness linked to severe COVID
NCT ID NCT06762002
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study follows 500 adults in France who have either a genetic defect or autoantibodies that weaken their type I interferon immune response. Researchers will collect blood samples and health data over 1 to 4 years to track infections, autoimmune diseases, and cancers. The goal is to better understand and manage these immune deficiencies, but no new treatments are being tested.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could improve how doctors monitor and manage patients with type I interferon deficiencies, potentially reducing severe infections.
What could go wrong
This is an observational study, not a treatment trial. It will not directly cure or treat any disease, and results may take years to translate into clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cic Bichat
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Creteil
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic La Salpetriere
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Lille
RECRUITINGLille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Montpellier
RECRUITINGMontpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Necker
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic St Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cic Tours
RECRUITINGTours, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
LYON HCL
RECRUITINGLyon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact